Developmental Research Program

RPCI-UPCI卵巢癌孢子开发研究计划是一个支持创新的、潜在的高风险/高回报的研究人员发起的具有成熟潜力的卵巢癌研究项目的平台，这些项目将把基础和/或人群研究成果转化为以人类临床标本/患者群体为重点的研究。此外，发展研究计划的资金将通过鼓励将试点项目发展为合作的、多研究人员的、多机构的翻译研究计划，或作为RPCI-UPCI卵巢癌孢子的个别研究项目的替代品来发挥杠杆作用。因此，发展研究计划项目是孢子成功的最终衡量标准，并形成各个机构未来转化性卵巢癌研究的基础，因为它们是下一代R01、P01、联盟和孢子赠款的跳板。来自已建立卵巢癌研究计划的教职员工或有意过渡到转化性卵巢癌研究的教职员工的提案将由执行委员会评估其科学价值。发展研究计划负责人将召集NIH格式研究部分，并将NIH R21类型的申请分配给两名科学家和一名患者倡导审查员。审查结果将在行政核心中汇总，并提交给内部咨询委员会，以便提出供资建议。发展研究计划将每年资助三到四个项目，资助水平为每年50,000美元。前景看好的项目有资格获得额外一年的资助，但为了在吸引新的创新项目方面保持最大的灵活性，每年不超过一个项目将被续签。发展研究计划的独特优势在于，它能够及时向高风险/试点项目提供重要的财政支持，以开发关键的初步数据，提供灵活的机制，通过使用执行委员会和内部咨询委员会的正式申请程序，对新的倡议或令人兴奋的发现做出快速反应，或者通过RPCI-UPCI卵巢癌孢子首席调查员的特别基金获得更快但更少的资金。

The Developmental Research Program of the RPCI-UPCI Ovarian Cancer SPORE is a platform to support innovative, potentially high-risk/high-reward, investigator-initiated projects with the potential for maturation into translational ovarian cancer research projects that will transit basic and/or population research findings into research focused on human clinical specimens/patient populations. Furthermore, the funds of the Developmental Research Program will be leveraged by encouraging the development of the pilot projects into collaborative, multi-investigator, multi-institutional translational research programs, or as replacements for the Individual Research Projects of the RPCI-UPCI Ovarian Cancer SPORE. Therefore, the Developmental Research Program projects are the ultimate measure of the success of a SPORE, and form the base for future translational ovarian cancer research at the individual institutions since they are the springboard for the next generation of R01, P01, Consortium, and SPORE grants. Proposals from faculty with established ovarian cancer research programs, or faculty interested in transitioning to translational ovarian cancer research, will be evaluated by the Executive Committee for scientific merit. The Development Research Program Leaders will convene a NIH format study section and assign NIH R21- type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. The Developmental Research Program will fund three to four projects per year at a funding level of $50,000 per year. Highly promising projects are eligible for an additional year of funding, but in order to maintain maximal flexibility in attracting new innovative projects, no more than one project per year will be a renewal. The unique strengths of the Developmental Research Program lie in its ability to provide significant financial support in a timely manner to high-risk/pilot projects to develop critical preliminary data, provide a flexible mechanism that can respond rapidly to new initiatives or exciting findings through a formal application procedure using the Executive Committee and Internal Advisory Board, or receive even quicker but lesser funds through an ad hoc award from the Discretionary Fund of the RPCI-UPCI Ovarian Cancer SPORE Principal Investigator.